Skip to main content
Top
Published in: Cancer Causes & Control 8/2009

01-10-2009 | Letter to the Editor

Re: Vitamin and mineral use and risk of prostate cancer: the case–control surveillance: Zhang et al. Cancer Causes Control. 2008 Dec 18 [Epub ahead of print]

Authors: Renty B. Franklin, Leslie C. Costello

Published in: Cancer Causes & Control | Issue 8/2009

Login to get access

Excerpt

The report of Zhang et al. [1] concludes that, “long-term zinc intake from multivitamins or single supplements was associated with a doubling in risk of prostate cancer adds to the growing evidence for an unfavorable effect of zinc on prostate cancer carcinogenesis.” Such conclusions have serious consequences on the thinking and actions of the medical, scientific, and public communities. In the absence of a knowledgeable background, most readers will accept at face value the report’s conclusion regarding zinc supplement use and the development of prostate cancer. Therefore, it is important to question and raise serious issues regarding the appropriateness of the study and its conclusions. In this brief response, we highlight some important specific concerns regarding the findings of Zhang et al.; and direct the reader to the Taubes report and responses [2, 3] and to our review [4] for more extensive descriptions. …
Appendix
Available only for authorised users
Footnotes
1
Gonzalez A, Peters U, Lampe JW, White Emily (2009) Zinc intake from supplements and diet and prostate cancer. Nutrition Cancer 61:206–215.
 
Literature
1.
go back to reference Zhang Y, Coogan P, Palmer JR, Strom BL, Rosenberg L (2008) Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. Cancer Causes Control, 2008 Dec 18 [Epub ahead of print] Zhang Y, Coogan P, Palmer JR, Strom BL, Rosenberg L (2008) Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. Cancer Causes Control, 2008 Dec 18 [Epub ahead of print]
3.
go back to reference (1995) Letters re: the discipline of epidemiology. Science 269:1325–1328 (1995) Letters re: the discipline of epidemiology. Science 269:1325–1328
5.
go back to reference Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL (2003) Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 95:1004–1007PubMedCrossRef Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL (2003) Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 95:1004–1007PubMedCrossRef
6.
go back to reference Kristal AR, Stanford JL, Cohen JH, Wicklund K, Patterson RE (1999) Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomark Prev 8:887–892 Kristal AR, Stanford JL, Cohen JH, Wicklund K, Patterson RE (1999) Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomark Prev 8:887–892
7.
go back to reference Kolonel LN, Yoshizawa CN, Hankin JH (1988) Diet and prostatic cancer: a case-control study in Hawaii. Am J Epidemiol 127:999–1012PubMed Kolonel LN, Yoshizawa CN, Hankin JH (1988) Diet and prostatic cancer: a case-control study in Hawaii. Am J Epidemiol 127:999–1012PubMed
9.
go back to reference West DW, Slattery ML, Robison LM, French TK, Mahoney AW (1991) Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control 2:85–94. doi:10.1007/BF00053126 PubMedCrossRef West DW, Slattery ML, Robison LM, French TK, Mahoney AW (1991) Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control 2:85–94. doi:10.​1007/​BF00053126 PubMedCrossRef
13.
go back to reference Gori GB (1995) Letters re: the discipline of epidemiology. Science 269:1327–1328PubMed Gori GB (1995) Letters re: the discipline of epidemiology. Science 269:1327–1328PubMed
Metadata
Title
Re: Vitamin and mineral use and risk of prostate cancer: the case–control surveillance: Zhang et al. Cancer Causes Control. 2008 Dec 18 [Epub ahead of print]
Authors
Renty B. Franklin
Leslie C. Costello
Publication date
01-10-2009
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 8/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-009-9363-6

Other articles of this Issue 8/2009

Cancer Causes & Control 8/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine